Last quarter (Q4 2023), Tryp Therapeutics Inc's total revenue was C$―, a decrease of ― from the same quarter last year. In Q4, Tryp Therapeutics Inc's net income was C$-1.16M. See Tryp Therapeutics Inc’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Aug 23	Aug 22	Aug 21	Aug 20
Total Revenue	-	-	-	-	C$ 0.00
Cost of Revenue	-	-	-	-	-
Gross Profit	-	-	-	-	-
Operating Expense	C$ 4.63M	C$ 5.11M	C$ 7.36M	C$ 7.29M	C$ 422.62K
Operating Income	C$ -4.63M	C$ -5.11M	C$ -7.36M	C$ -7.29M	C$ -422.62K
Net Non Operating Interest Income Expense	C$ 3.67K	C$ 1.75K	C$ 3.25K	C$ -10.93K	C$ 0.00
Other Income Expense	C$ 134.30K	C$ 134.30K	-	C$ -977.53K	-
Pretax Income	C$ -4.79M	C$ -5.27M	C$ -7.49M	C$ -8.25M	C$ -422.62K
Tax Provision	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-
Net Income Common Stockholders	C$ -4.79M	C$ -5.27M	C$ -7.49M	C$ -8.25M	C$ -422.62K
Basic EPS	C$ -0.05	C$ -0.05	C$ -0.10	C$ -0.14	C$ >-0.01
Diluted EPS	C$ -0.05	C$ -0.05	C$ -0.10	C$ -0.14	C$ >-0.01
Basic Average Shares	C$ 385.68M	C$ 96.42M	C$ 78.06M	C$ 57.51M	C$ 66.32M
Diluted Average Shares	C$ 385.68M	C$ 96.42M	C$ 78.06M	C$ 57.51M	C$ 66.32M
Dividend Per Share	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-
Total Expenses	C$ 4.63M	C$ 5.11M	C$ 7.36M	C$ -7.29M	C$ 422.62K
Net Income From Continuing And Discontinued Operation	C$ -4.79M	C$ -5.27M	C$ -7.49M	C$ -8.25M	C$ -422.62K
Normalized Income	C$ -4.15M	C$ -3.87M	C$ -5.51M	C$ -5.11M	C$ -422.62K
Interest Expense	-	-	-	-	-
EBIT	C$ -4.79M	C$ -5.27M	C$ -7.49M	C$ -8.25M	C$ -422.62K
EBITDA	C$ -4.79M	C$ -5.27M	C$ -7.49M	C$ -8.25M	C$ -422.62K

Currency in CAD

Tryp Therapeutics Inc Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing